Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026)
Evaxion A's (EVAX) quarterly Asset Utilization Ratio came in at 0.29 in Q1 2026, up 65.71% YoY from 0.17 in Q1 2025, and up 11.71% on a QoQ basis from 0.26 in Q4 2025.
Evaxion A (EVAX) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Evaxion A (EVAX) has 2 years of Asset Utilization Ratio data on file, last reported at 0.29 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 65.71% year-over-year to 0.29 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.29 (up 65.71% YoY) and the FY2025 annual result came in at 0.37, up 39.69% from the prior year.
- Asset Utilization Ratio improved to 0.29 in Q1 2026, from 0.26 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.29 in Q3 2025 to a low of 0.13 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | 0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.29 |
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.17 |